Tirzepatide Research Review — Week 12 Progress

The SURPASS and SURMOUNT trial data continues to be the gold standard reference for tirzepatide research. At the 12-week mark in clinical trials, the dual GIP/GLP-1 agonism shows clear separation from single-agonist approaches.

The glucose-dependent insulinotropic mechanism means hypoglycemia risk remains low even at higher doses — a significant advantage over older approaches documented in the safety data.

Reviewing the SURMOUNT-3 data on weight regain after discontinuation. This is the area where more research is critically needed.